| Literature DB >> 32659965 |
Mélanie M Leroux1, Zahra Doumandji1, Laetitia Chézeau2, Laurent Gaté2, Sara Nahle1, Romain Hocquel1, Vadim Zhernovkov3, Sylvie Migot1, Jafar Ghanbaja1, Céline Bonnet4, Raphaël Schneider5, Bertrand H Rihn1, Luc Ferrari1, Olivier Joubert1.
Abstract
There are many studies concerning titanium dioxide (TiO2) nanoparticles (NP) toxicity. Nevertheless, there are few publications comparing in vitro and in vivo exposure, and even less comparing air-liquid interface exposure (ALI) with other in vitro and in vivo exposures. The identification and validation of common markers under different exposure conditions are relevant for the development of smart and quick nanotoxicity tests. In this work, cell viability was assessed in vitro by WST-1 and LDH assays after the exposure of NR8383 cells to TiO2 NP sample. To evaluate in vitro gene expression profile, NR8383 cells were exposed to TiO2 NP during 4 h at 3 cm2 of TiO2 NP/cm2 of cells or 19 μg/mL, in two settings-submerged cultures and ALI. For the in vivo study, Fischer 344 rats were exposed by inhalation to a nanostructured aerosol at a concentration of 10 mg/m3, 6 h/day, 5 days/week for 4 weeks. This was followed immediately by gene expression analysis. The results showed a low cytotoxic potential of TiO2 NP on NR8383 cells. Despite the absence of toxicity at the doses studied, the different exposures to TiO2 NP induce 18 common differentially expressed genes (DEG) which are involved in mitosis regulation, cell proliferation and apoptosis and inflammation transport of membrane proteins. Among these genes, we noticed the upregulation of Ccl4, Osm, Ccl7 and Bcl3 genes which could be suggested as early response biomarkers after exposure to TiO2 NP. On the other hand, the comparison of the three models helped us to validate the alternative ones, namely submerged and ALI approaches.Entities:
Keywords: ALI; macrophages; nanoparticles; rat; titanium dioxide; toxicogenomics; transcriptomics
Mesh:
Substances:
Year: 2020 PMID: 32659965 PMCID: PMC7402355 DOI: 10.3390/ijms21144855
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1TEM images of titanium dioxide nanoparticles. TiO2 NPs (NM-105) in anatase dominant form.
TiO2 NP characteristics.
| Nanoparticle | Primary Size (nm) | Secondary Size (nm) | Zeta Potential (mV) | Specific Surface Aera (m2/g) | Provider |
|---|---|---|---|---|---|
|
| 21.5 ± 7.2 | 170 ± 1.5 | 11.1 ± 0.7 | 51 | Joint Research Center |
Figure 2(A) Cytotoxicity of TiO2 NP (24 h exposure) to NR8383 by WST-1 test and (B) loss of membrane integrity by LDH release measurement. Non exposed cells are negative control (C−) and positive control (C+) for LDH are cells exposed to the lysis buffer (Triton 5%) during 15 min before the measure. Data are presented as means ± standard deviation (SD) of the four biologic replicates.
Figure 3Volcano plots displaying differentially expressed genes between NM-105 treated and control samples for (A) in vitro submerged, (B) in vivo lung and (C) in vitro ALI exposures. Vertical axis corresponds to the -log10(FDR corrected p-value) and the horizontal axis displays the log2-fold change value. The vertical lines correspond to 1.3-fold up and down changes (log2FC = 0.38), respectively, and the horizontal line represents FDR corrected p-value of 0.05 (-log10P = 1.3). Red dots represent the up- and downregulated expressed genes.
Total number of differentially expressed genes (FDR corrected p-value < 0.05).
| Groups | FC 1.3 | FC 1.5 | FC3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Up | Down | Total | Up | Down | Total | Up | Down | Total | |
| 4612 | 5224 |
| 3939 | 3956 |
| 345 | 1376 |
| |
| 439 | 412 |
| 108 | 94 |
| 0 | 1 |
| |
| lung | 898 | 579 |
| 559 | 221 |
| 64 | 5 |
|
Figure 4Venn diagram of differentially deregulated genes after TiO2 NP in vivo (lung), in vitro submerged and ALI (Vitrocell) exposures (FDR corrected p-value < 0.05). Genes were filtered with different fold change cutoff: In vitro submerged: 2.8, In vitro ALI Vitrocell: 1.3 and In vivo lung: 1.3.
Gene set enrichment analysis (GSEA) functional annotation of differentially expressed genes (DEG) in the three conditions.
| Gene Set | |||
|---|---|---|---|
|
| |||
| IL6_JAK_STAT3_SIGNALING | 1.25 × 10−7 | 7.42 × 10−2 | 3.82 × 10−2 |
| MYC_TARGETS_V2 | 4.30 × 10−6 | 7.42 × 10−2 | 3.65 × 10−2 |
|
| |||
| E2F_TARGETS | 1.04 × 10−14 | 8.40 × 10−7 | – |
| G2M_CHECKPOINT | 7.96 × 10−11 | 7.00 × 10−3 | – |
| MYC_TARGETS_V1 | 1.08 × 10−4 | 7.00 × 10−3 | – |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 9.03 × 10−2 | 3.84 × 10−2 | – |
|
| |||
| UV_RESPONSE_DN | 6.21 × 10−3 | – | 6.73 × 10−2 |
| TNFA_SIGNALING_VIA_NFKB | 9.43 × 10−3 | – | 1.46 × 10−3 |
|
| |||
| ALLOGRAFT_REJECTION | 1.25 × 10−7 | – | – |
| MTORC1_SIGNALING | 5.73 × 10−7 | – | – |
| INFLAMMATORY_RESPONSE | 1.48 × 10−6 | – | – |
| MYOGENESIS | 4.30 × 10−6 | – | – |
| INTERFERON_GAMMA_RESPONSE | 8.61 × 10−4 | – | – |
| COMPLEMENT | 5.05 × 10−3 | – | – |
| ANGIOGENESIS | 5.82 × 10−3 | – | – |
| IL2_STAT5_SIGNALING | 2.32 × 10−2 | – | – |
| CHOLESTEROL_HOMEOSTASIS | 3.89 × 10−2 | – | – |
| APICAL_JUNCTION | 4.49 × 10−2 | – | – |
| GLYCOLYSIS | 6.27 × 10−2 | – | – |
| HEDGEHOG_SIGNALING | 6.27 × 10−2 | – | – |
| WNT_BETA_CATENIN_SIGNALING | 8.13 × 10−2 | – | – |
| COAGULATION | 8.89 × 10−2 | – | – |
| TGF_BETA_SIGNALING | 9.03 × 10−2 | – | – |
| OXIDATIVE_PHOSPHORYLATION | 9.03 × 10−2 | – | – |
| UNFOLDED_PROTEIN_RESPONSE | 9.55 × 10−2 | – | – |
| UV_RESPONSE_UP | – | 7.42 × 10−2 | – |
| MITOTIC_SPINDLE | – | – | 9.38 × 10−3 |
| DNA_REPAIR | – | – | 3.65 × 10−2 |
| PROTEIN_SECRETION | – | – | 4.11 × 10−2 |
Common genes between the three exposures (different group functions are highlighted in different colors, detailed information where found in GeneCards, UniProt, String, protein Atlas and PubMed databases). Colors in the function group column are used to identify common elements easily.
| Name Gene Protein | FC | Protein Function | Function Group *KEGG Pathway | Pathologies Associated | ||
|---|---|---|---|---|---|---|
| Vivo | Vitro | ALI | ||||
|
| 1.97 | −8.43 | −1.33 | The CENPF protein is a part of the corona of kinetochore complex which interacts with microtubules and participate to a precise and rapid chromosome segregation. [ |
| |
| 2.66 | −4.05 | −1.31 | Component of the essential kinetochore-associated NDC80 complex, required for chromosome segregation and spindle checkpoint activity, required for kinetochore integrity. [ |
| ||
| 2.11 | −3.35 | −1.38 | Plus-end directed kinesin-like motor enzyme involved in mitotic spindle assembly [ |
| ||
| 2.50 | −8.91 | −1.39 | Belongs to the TRAFAC class myosin–kinesin ATPase superfamily. kinesin family (String DB) |
| ||
| 1.67 | −4.64 | −1.36 | serine/threonine–protein kinase that plays a central role in centriole duplication; (UniProt) |
| ||
| 3.31 | −4.45 | −1.33 | DEP domain containing 1 (DEPDC1) is a highly conserved protein among many species. DEPDC1 was overexpressed in different types of cancers. [ | |||
| 1.46 | −3.59 | −1.44 | Multifunctional protein with various roles in different cellular compartments. May act in a redox sensitive manner. In the nucleus is an abundant chromatin-associated non-histone protein involved in transcription, chromatin remodeling and V(D)J recombination. |
| ||
| 1.43 | −3.54 | −1.58 | Receptor for ADP and ATP coupled to G-proteins. Required for normal platelet aggregation and blood coagulation. [ | |||
| 1.71 | 3.72 | 2.15 | Monokine with inflammatory and chemokinetic properties; (UniProt) |
| ||
| 5.61 | 3.53 | 1.47 | Chemotactic factor attracts monocytes and eosinophils, but not neutrophils. (String DB) |
| ||
| 1.38 | 6.84 | 1.41 | Growth regulator. It regulates cytokine production, including IL-6, G-CSF and GM-CSF; (UniProt) |
| ||
| 1.35 | −5.86 | −1.32 | transcriptional regulator that acts as a repressor or an activator; (UniProt) |
| ||
| 1.47 | −7.00 | −1.32 | Mobilization and differentiation of bone marrow (BM)-derived cells [ | |||
| 1.69 | 4.60 | 1.41 | BCL3 (BCL3 transcription Coactivator) is a proto-oncogene candidate. Its related pathways are Apoptosis-related network and Common cytokine receptor gamma-chain family signaling pathways. |
|
| |
| −1.38 | 7.10 | 1.74 | This gene encodes an oxidative stress response protein that regulates cell death. Expression regulated by p53 and induced by DNA damage. The protein regulates apoptosis by inducing cytochrome c release from mitochondria. Key regulator of both inflammatory and anti-inflammatory molecules. The loss of this protein correlates with uncontrolled cell growth and tumor formation. (GeneCards) |
|
| |
| −1.41 | 3.01 | −1.57 | Member of the protein tyrosine phosphatase (PTP) family. PTPs are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle and oncogenic transformation. |
|
| |
| −1.57 | 3.32 | 1.48 | The product of this gene belongs to the phosphatase 2A (PP2A) regulatory subunit B family. PP2A it is implicated in the negative control of cell growth and division. The phosphorylated form mediates the interaction between PP2A and AKT1. (GeneCards) |
|
| |
| 1.54 | −2.90 | −1.38 | Among its related pathways are B Cell Receptor Signaling Pathway and AKT Signaling Pathway. |
| ||
(A) Gene ontology (GO) biologic process (20 most dysregulated GO-term); (B) KEGG pathways and (C) reactome pathways of the 18 common dysregulated genes (analyzed by String 11.1 Database).
|
|
|
|
|
| GO:0071346 | cellular response to interferon-gamma | 2 of 39 | 0.0265 |
| GO:0070098 | chemokine-mediated signaling pathway | 2 of 30 | 0.0265 |
| GO:0050921 | positive regulation of chemotaxis | 2 of 68 | 0.0265 |
| GO:0048522 | positive regulation of cellular process | 7 of 2201 | 0.0265 |
| GO:0048247 | lymphocyte chemotaxis | 2 of 20 | 0.0265 |
| GO:0045087 | innate immune response | 3 of 217 | 0.0265 |
| GO:0044089 | positive regulation of cellular component biogenesis | 3 of 220 | 0.0265 |
| GO:0040011 | locomotion | 4 of 404 | 0.0265 |
| GO:0030593 | neutrophil chemotaxis | 2 of 23 | 0.0265 |
| GO:0016477 | cell migration | 3 of 293 | 0.0265 |
| GO:0010469 | regulation of signaling receptor activity | 4 of 325 | 0.0265 |
| GO:0009967 | positive regulation of signal transduction | 4 of 638 | 0.0265 |
| GO:0006955 | immune response | 4 of 386 | 0.0265 |
| GO:0006954 | inflammatory response | 3 of 250 | 0.0265 |
| GO:0006935 | chemotaxis | 3 of 172 | 0.0265 |
| GO:0006928 | movement of cell or subcellular component | 4 of 486 | 0.0265 |
| GO:0002687 | positive regulation of leukocyte migration | 2 of 63 | 0.0265 |
| GO:0002548 | monocyte chemotaxis | 2 of 12 | 0.0265 |
| GO:0071347 | cellular response to interleukin-1 | 2 of 75 | 0.0267 |
| GO:0051173 | positive regulation of nitrogen compound metabolic process | 5 of 1184 | 0.0267 |
|
|
|
|
|
| rno04060 | Cytokine–cytokine receptor interaction | 3 of 217 | 0.0130 |
|
|
|
|
|
| RNO-68877 | Mitotic prometaphase | 4 of 168 | 0.00063 |
| RNO-5663220 | RHO GTPases activate formins | 3 of 116 | 0.0013 |
| RNO-2500257 | Resolution of sister chromatid cohesion | 3 of 100 | 0.0013 |
| RNO-141444 | Amplification of signal from unattached kinetochores | 3 of 80 | 0.0013 |
| RNO-2467813 | Separation of sister chromatids | 3 of 149 | 0.0019 |
Figure 5Heatmap of common dysregulated genes, fold changes are represented by a color scale (p-value < 0.05).
Figure 6Interactions and function groups of the 18 common dysregulated genes (adapted from an analyze by String 11.1 Database, functions groups were determined through UniProt, GeneCards and PubMed researches).